|
¸¶ÀϽºÅæ¼Ä¡ |
Country Medical Director/À¯·´°èÇÕÀÛÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
5³â¡è |
ä¿ë½Ã |
03.11 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
Associate/Director, Clinical Operations, Medical Device
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
10.23 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
clinical marketing manager
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
5³â¡è |
ä¿ë½Ã |
01.02 |
|
|
¿ÍÀÌ¿¥Ä¿¸®¾î |
[ÄÚ½º´Ú »óÀå À¯¸Á ¹ÙÀÌ¿À ±â¾÷] Global IR Â÷Àå±Þ ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
±¤°í/È«º¸/PR/»çº¸ |
5³â¡è |
ä¿ë½Ã |
05.25 |
|
|
(ÁÖ)ÀÎÄÚ¸®¾ÆÇÁ·ÎÆä¼Å³Î |
[¿Ü±¹°è]¿Ü±¹°è Technical Application Specialist(Biopharm
¼¿ï °³²±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
09.18 |
|
|
(ÁÖ)ÀÎÄÚ¸®¾ÆÇÁ·ÎÆä¼Å³Î |
[¿Ü±¹°è]»ý¸í°øÇÐ Áø´ÜÀåºñ,ºÐ¼®Àåºñ Service Engineer ´ë¸®
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
AS/Á¤ºñ/¼ö¸®/¼³Ä¡ |
5³â¡è |
ä¿ë½Ã |
04.09 |
|
|
Ä¿¸®¾îÆ÷Ä¿½º |
Çã°¡ RA ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) ÀçÇÐ |
¶óÀ̼¾½ºIn/Out |
5³â¡è |
ä¿ë½Ã |
03.14 |
|
|
ÇÁ·ÎÇÚÁîÄÚ¸®¾Æ |
»óÀåÁ¦¾à»ç »ç³»º¯È£»ç(5~10³â)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ç¹«/Ãѹ«/¹ý¹«/ƯÇã |
5³â¡è |
ä¿ë½Ã |
05.03 |
|
|
Çì´Ï¾Ø¸ÓÄÚÀÌ |
Pharmacovigilance (MI) Specialist / Regulatory Affairs
¼¿ï °³²±¸, ¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
5³â¡è |
ä¿ë½Ã |
03.14 |
|
|
Çì´Ï¾Ø¸ÓÄÚÀÌ |
CRA (Clinical Research Associate)
¼¿ï °³²±¸, ¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
09.18 |
|
|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[·ÎÄÃCRO] RAµð·ºÅÍ
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
5³â¡è |
ä¿ë½Ã |
03.25 |
|
|
KY Consulting Group |
CMO ¸¶ÄÉÆà ÆÀÀå
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
5³â¡è |
ä¿ë½Ã |
08.28 |
|
|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[¿Ü±¹°èÁ¦¾à»ç] Legal Compliance Manager
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
04.19 |
|
|
Á¦À̾ØÆÄÆ®³ÊÁîÄÚ¸®¾Æ(ÁÖ) |
[±¹³»Á¦¾à»ç] ÇØ¿Ü¿µ¾÷
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¹«¿ª/ÇØ¿Ü¿µ¾÷/Åë¹ø¿ª |
5³â¡è |
ä¿ë½Ã |
03.28 |
|
|
JN Partners |
[À¯¸íÁ¦¾à»ç] ±Û·Î¹ú BD 3¸í (ÁÖÀÓ~Â÷Àå)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
5³â¡è |
ä¿ë½Ã |
03.21 |
|